263.1 Advanced donor age does not impact graft survival in a large single centre lung transplant cohort
Dr. Andrei Darie, Australia
263.2 Developing a multidimensional immunological toolset to facilitate rejection diagnosis and mechanistic understanding of rejection, infection and chronic lung allograft dysfunction after human lung transplantation
Dr. Jiao Wenyu, People's Republic of China
263.3 Anti-MDA5 antibody as a monitoring marker of disease recurrence after lung transplantation in rapidly progressive interstitial lung disease patients
Prof. Eun-Suk Kang, Korea
263.4 Donor-derived cell-free DNA is a valuable surveillance tool after single lung transplantation: Multi-center analysis
Ambalavanan Arunachalam, United States
263.5 Pediatric lung transplantation in China, 2019-2023
Jingyu Chen, People's Republic of China
263.7 Lung transplantation for pneumoconiosis in 2015-2023: Experience from two largest lung transplantation centers in China
Dr. Hua Wenjie, People's Republic of China
263.8 Serratus anterior plane block for analgesia after lung transplant
Dr. Shui Yu, People's Republic of China
263.9 Pre-transplant angiotensin type 1 receptor antibodies are associated with acute kidney injury post-lung transplant
Prof. Gregory Snell, Australia
263.10 Exploring acceptability of lung uDCD among clinical and community stakeholders in New York City
Dr. Jingzhi Xu, United States
263.11 ACR detected with cryobiopsy in lung transplant recipients is not associated with elevated dd-cfDNA
Dr. Mace Matthew Schuurmans, Switzerland
263.12 Prone Positioning in Potential Organ Donors. Preliminary Results. PRODON-AR Multicenter Study